New Invention Profile
| Publication No: | IN202211066609 [India] | Application No: | IN202211066609 |
| Title: | Composition for treating paclitaxel-resistant breast cancer | ||
| Publication Date: | 24-05-2024 | File Date: | 18-11-2022 |
| Inventor(s): | Sameer Ahmad Mir; Shahnawaz Khan; Sameer Ullah Khan; Masroor Ahmad Paddar; Loveleena Kaur Anand; Mir Shahid Maqbool; Atul Kumar; Anil Padala; Gousia Chashoo; Utpal Nandi; Gurdarshan Singh; Bhahwal Ali Shah; Qazi Naveed Ahmed; Fayaz Malik; Baseerat Hamza; Kaneez Fatim; Nadiem Nazir; Ashish Dogra; Amit Kumar; Govind Yadav | ||
| IPC Classification: | A61P 35/00, A61K 31/337, A61P 35/04, A61K 39/00, A61K 45/06 | ||
| Abstract: | The compound IIIM-152 and its derivatives have been reported as potent stem cell modulators by down-regulating beta-catenin signaling. TNBCs are highly aggressive cancers and chemotherapy like Paclitaxel remains one of the primary treatment options. However, CSCs remains non-responsive to the Paclitaxel treatment leads to disease recurrence and metastasis and is one of the major clinical challenges. The Combinatorial treatment of IIIM-in vitro eliminates the Paclitaxel Resistant Cancer Stem Cells, whereas Paclitaxel only treatment is unable to target CSCs subpopulation. Similarly, a combination of Paclitaxel (10mg/kg)+ IIIM152 (50mg/kg and 100mg/kg), in tumor bearing mice showed significant reduction in tumor burden and decrease in number of Cancer Stem Cells in excised tumors. The combination of IIIM-152 and Paclitaxel proves to be clinically efficacious in treating the Paclitaxel non-responsive highly aggressive residual cancer stem cells to achieve long lasting treatment and addresses huge unmet medical need. |
||
CSIR-Indian Institute of Integrative Medicine[CSIR-IIIM]
: director[at]iiim[dot]res[dot]in
:91-191-2585222
:https://iiim.res.in
: director[at]iiim[dot]res[dot]in
:91-191-2585222
:https://iiim.res.in
Industrial Applications
Others [ROOT]